lilly tirzepatide shortage FDA makes end of Zepbound, Mounjaro official Lilly's weight-loss drug removed from

Zepbound received FDA approval specifically for adults with moderate-to-severe obstructive sleep apnea who also have obesity

In Phase 3 TRIUMPH-4 (Eli Lilly, December 11, 2025), the 12 mg arm averaged 28.7% body weight loss at 68 weeks

Although manifestations of neurological dysfunction often point to TD and may sometimes accompany gastrointestinal beriberi (17, 64), it has been also noted that chronic mild deficiency may present with gastrointestinal symptoms under entirely normal neurological exams in well-nourished, non-alcoholic patients (6568)

Nunca suspenda la tirzepatida u otros medicamentos sin consultar primero con su proveedor de atencin mdica